David Printzenhoff
Pfizer
6 Papers
4 Citations
David Printzenhoff is an academic researcher from Pfizer. The author has contributed to research in topics: Sodium channel & Channel blocker. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels
Ken McCormack,Sonia Santos,Mark L. Chapman,Douglas S. Krafte,Brian E. Marron,Christopher William West,Michael J. Krambis,Brett M Antonio,Shannon G. Zellmer,David Printzenhoff,Karen Padilla,Zhixin Lin,P. Kay Wagoner,Nigel Alan Swain,Stupple Paul Anthony,Marcel J. de Groot,Richard P. Butt,Neil A. Castle +17 more
TL;DR: A new class of subtype selective small molecule sodium channel inhibitors that interact with a region of the channel that controls voltage sensitivity is described, which may enable development of selective therapeutic interventions with reduced potential for toxicity.
Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release
Aristos J. Alexandrou,Adam R. Brown,Mark L. Chapman,Mark Estacion,Jamie Turner,Malgorzata A. Mis,Anna Wilbrey,Elizabeth C. Payne,Alex Gutteridge,Peter J. Cox,Rachel Doyle,David Printzenhoff,Zhixin Lin,Brian E. Marron,Christopher William West,Nigel Alan Swain,R. Ian Storer,Stupple Paul Anthony,Neil A. Castle,James A. Hounshell,Mirko Rivara,Andrew D. Randall,Sulayman D. Dib-Hajj,Douglas S. Krafte,Stephen G. Waxman,Manoj K. Patel,Richard P. Butt,Edward B. Stevens +27 more
TL;DR: It is reported that Nav1.7 is the predominant functional TTX-sensitive Nav in mouse and human nociceptors and contributes to the initiation and the upstroke phase of the nOCiceptor action potential, and a role for Nav 1.7 in influencing synaptic transmission in the dorsal horn of the spinal cord as well as peripheral neuropeptide release in the skin is confirmed.
The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics.
David C. Pryde,Nigel Alan Swain,Stupple Paul Anthony,Christopher William West,Brian E. Marron,C. J. Markworth,David Printzenhoff,Zhixin Lin,Peter J. Cox,Ryoichi Suzuki,S. McMurray,Gareth Waldron,C. E. Payne,Joseph S. Warmus,Mark L. Chapman +14 more
TL;DR: The discovery of an aryl ether series of potent and selective Nav1.3 inhibitors, based on structural analogy to a similar series of compounds shown to bind to the domain IV voltage sensor region of Nav channels, is described.
Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms.
Neil A. Castle,David Printzenhoff,Shannon G. Zellmer,Brett Antonio,Alan D. Wickenden,Christopher Silvia +5 more
TL;DR: Overall, the PatchXpress and IonWorks electrophysiology platforms have individual strengths that make them complementary to each other and both platforms are capable of measuring state dependent modulation of sodium channels.
A novel selective and orally bioavailable Nav1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability
Claire Elizabeth Payne,Adam R. Brown,Jonathon W Theile,Alexandre J.C. Loucif,Aristos J. Alexandrou,Mathew D Fuller,John H. Mahoney,Brett M Antonio,Aaron C. Gerlach,David Printzenhoff,Rebecca L. Prime,Gillian Stockbridge,Anthony J. Kirkup,Anthony W Bannon,Steve England,Mark L. Chapman,Sharan K. Bagal,Rosemarie Roeloffs,Uma Anand,Praveen Anand,Peter J. Bungay,Kemp Mark Ian,Richard P. Butt,Edward B. Stevens +23 more
TL;DR: The effects of PF‐01247324, a new generation, selective, orally bioavailable Nav1.8 channel blocker of novel chemotype, is described.